Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...

Recommendations are presented to address infectious complications associated with regional anesthesia and pain management.

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...